-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the beginning of June, the industry reported the retirement of the executives of two multinational pharmaceutical companies in Greater China.
One is that Bayer Group officials announced that Jiang Wei, president of the Greater China Region, decided not to renew the contract and retire from Bayer Group based on family arrangements.
One is that Miao Tianxiang, chairman of Huizhi Pharmaceutical's Greater China Region, retired.
It is understood that Bayer has internally made arrangements for the step-by-step handover:
On July 1, Jiang Wei was first handed over as a member of the Global Executive Committee of Bayer Group's Prescription Drug Division and the position of President of the China Region.
Then on September 30, Jiang Weijiao assumed the position of President of Bayer Group Greater China, and was also taken over by Zhou Xiaolan.
Jiang Wei and Miao Tianxiang are both very famous in the industry.
After graduating with a master's degree in 1993, Jiang Wei started his career in the pharmaceutical industry.
Under its leadership, Bayer’s prescription drug division has become one of the top three multinational companies in China’s pharmaceutical industry, and has established a market leading position in all its therapeutic areas, including cardiovascular disease, diabetes, anti-thrombosis, women’s health, In the field of hemophilia, respiratory diseases and tumor treatment, China has become one of the strategic pillars of Bayer's global prescription drug division.
The last time Jiang Wei was interviewed as the President of Bayer Group Greater China was on March 17 this year.
In May 2018, Wu Xiaobin, who has served Pfizer for 15 years, left his job and started his own business.
On November 6, 2020, Shanghai-the global healthcare company that will be merged by Mylan and Pfizer Pretron-the corporate brand of Viatris was unveiled today at the third CIIE.
In addition to the changes in the heads of the two major multinational pharmaceutical companies in China, other multinational pharmaceutical companies also have important personnel changes.
On June 1, Ji Liwen, President and General Manager of Eli Lilly China, announced a personnel change to employees.
On June 2, GSK China announced the return of Zhu Ning to its employees: he will serve as vice president, head of market access and commercial operations, effective from June 15, and at the same time become a member of the leadership team of GSK China's prescription drugs and vaccines department , Working in Shanghai, reporting to Qi Xin, Vice President of GSK and General Manager of China Prescription Drugs and Vaccines.
On May 31, Hanhui Pharmaceutical announced major organizational restructuring and personnel appointments.
On May 28, Zhou Hong, President of Roche Pharmaceuticals China, announced to employees that Qian Wei, the general manager of Roche Pharmaceuticals China Oncology Division I and the acting head of the General Medicines Specialty Drugs Division, will leave his post on the 30th of next month due to personal reasons.
On May 26, Zhou You will join Sanofi Pasteur as the Chief Marketing Officer (CMO) and become a member of the Sanofi Pasteur China Management Committee.
He will work in Beijing and report directly to Sanofi Pasteur.
Zhang Heping, general manager of China.
